• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca, MRC Laboratory of Molecular Biology to launch joint research fund

AstraZeneca, MRC Laboratory of Molecular Biology to launch joint research fund

May 16, 2014
CenterWatch Staff

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of preclinical research projects aimed at better understanding the biology of disease.

Projects supported by the fund are likely to involve scientists from the two organizations working side by side, either within the MRC LMB at the Cambridge Biomedical Campus, the site of the company’s future strategic R&D center and global corporate headquarters, or in AstraZeneca and MedImmune research facilities. AstraZeneca would contribute up to $10 million and MRC LMB up to $5 million over five years, as well as in-kind scientific input to share knowledge and technologies. Decisions on which projects will receive support from the fund will be made jointly by MRC LMB and AstraZeneca.

Menelas Pangalos, executive vice president of innovative medicines and early development at AstraZeneca, said, “The aim of this joint fund will be to encourage truly innovative scientific thinking. We want to enable and encourage our scientists to push the boundaries of science, on the door step of our Cambridge headquarters, with one of the best scientific institutes in the world.”

Projects supported by the fund would be pre-competitive and would not be targeted specifically toward drug development, but would feed into the existing R&D activities of the two organizations, with the results published in peer-reviewed journals.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing